Solid IO Awarded European Partnership for Personalized Medicine Grant

Solid IO has been awarded €80 000 through the EP PerMed Fast Track Validation Programme, an EU-funded initiative aimed at accelerating the adoption of innovative personalized medicine solutions.

“This grant is an important recognition that our approach to precision diagnostics is aligned with Europe’s vision for next-generation personalized medicine. It reinforces our confidence that we are on the right path toward making immuno-oncology treatments more accessible and impactful for patients.”
– Noora Hujala, CEO, Solid IO

‍

Solid IO is developing a human-based diagnostic technology that mimics an individual patient’s biological response to help physicians predict how their patient’s cancer will respond to immunotherapies. With the support of this EU funding, and in collaboration with HUS Helsinki University Hospital as validation partner, it moves closer to delivering patient-specific diagnostics that can transform cancer care.

“At Helsinki University Hospital, we consider collaboration with early-stage, science-based startups highly important, as it enables us to bring new scientific breakthroughs to patients faster.”
– Taneli Raivio, Director of Research and Research Innovation (acting), HUS Helsinki University Hospital

‍

EP PerMed Programme's goal is to ensure that Europe remains at the forefront of personalized medicine by supporting start-ups and research teams in advancing their innovations toward clinical use and patient benefit.

“Solid IO is a great example of the type of innovation the EP PerMed Fast Track programme is designed to support. By advancing precision diagnostics in cancer care, the company addresses a critical need in personalized medicine and helps accelerate the arrival of human-relevant solutions.”
– Mohammed Ilyass Rahmouni, programme Manager, EP PerMed / EIT Health

‍

‍EP PerMed is a European partnership advancing personalised medicine through joint research, innovation and validation programmes. The Fast Track Call is one of the EU’s targeted funding instruments to speed up translation of promising healthcare innovations into real-world impact.

‍

HUS Helsinki University hospital is the largest hospital in Finland and one of the leading hospitals in the Nordics, combining top-level research and specialized care to provide effective and timely treatment for patients.

‍